Bruno Carlos
Sangro Gómez-Acebo

Catedrático de Universidad

Foto de Bruno Carlos

Foto de Idoia

Idoia
Bilbao Del Olmo

Colaboradora Clínica

Idoia Bilbao Del Olmo-rekin lankidetzan egindako argitalpenak (6)

2024

Comprehensive in silico CpG methylation analysis in hepatocellular carcinoma identifies tissue- and tumor-type specific marks disconnected from gene expression
Journal of Physiology and Biochemistry
Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Clinical and Molecular Hepatology, Vol. 30, Núm. 2, pp. 177-190

2022

Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib
Cancer Imaging, Vol. 22, Núm. 1

2021

Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage
Hepatology, Vol. 74, Núm. 5, pp. 2791-2807

2018

Pneumatocele during sorafenib therapy: First report of an unusual complication
Oncotarget, Vol. 9, Núm. 5, pp. 6652-6656

2015

Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: Analysis of the European multicentre trial SORAMIC
Liver International, Vol. 35, Núm. 2, pp. 620-626